Lumiliximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (primate/human) |
| Target | CD23 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| ChemSpider | none |
| UNII |
8Z13S29R5A  |
| Chemical and physical data | |
| Formula | C2115H3252N556O673S16 |
| Molar mass | 47.75 kg/mol |
 (what is this?) (verify) | |
Lumiliximab is a monoclonal antibody that targets CD23. It acts as an immunomodulator[1] and, as of October 2009, it is being investigated in Phase I and II clinical trials for the treatment of chronic lymphocytic leukemia.[2][3] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]
References
- 1 2 International Nonproprietary Names for Pharmaceutical Substances (INN). World Health Organization.
- ↑ Byrd, J. C.; Kipps, T. J.; Flinn, I. W.; Castro, J.; Lin, T. S.; Wierda, W.; Heerema, N.; Woodworth, J.; Hughes, S.; Tangri, S.; Harris, S.; Wynne, D.; Molina, A.; Leigh, B.; O'Brien, S. (2009). "Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia". Blood. 115 (3): 489–495. doi:10.1182/blood-2009-08-237727. PMC 2810983
. PMID 19843887. - ↑ Clinical trial number NCT00801060 at ClinicalTrials.gov
This article is issued from Wikipedia - version of the 9/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.